Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Phase 1DT-818Positive

AI Analysis

Summary

Design Therapeutics announced the initiation of patient dosing in a Phase 1 multiple ascending dose trial of DT-818 for Myotonic Dystrophy Type-1. This represents an early-stage clinical milestone for the investigational therapy.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.50

Phase 1Clinical TrialPatient DosingMultiple Ascending DoseRare Disease

Related Companies

$DSGN

Read the original article

Published by yahoo_finance on June 30, 2026 12:00 PM

Read Original